Shamrock Israel Growth Fund

The fund is backed by the capital of the Roy E. Disney family, managed through Shamrock Holdings, the Burbank-based investment office founded by Roy E. Disney in 1978. Stanley Gold has served as president and CEO of Shamrock Holdings since 1985, directing the family's investments across multiple asset classes and geographies.

The fund focuses on growth-stage companies, typically entering at Series B or C after product-market fit is established. This distinguishes it from the predominantly early-stage and seed-focused venture capital funds that operate in the Israeli market.

The fund concentrates on enterprise software, cybersecurity, fintech, digital health, and industrial technology. These sectors align with Israel's established technology strengths and the fund's preference for capital-efficient businesses with demonstrated commercial revenue.

It operates as a growth-equity arm of a single-family office, deploying permanent capital from the Disney family rather than third-party limited partner commitments. This structure eliminates fund-life constraints and LP redemption risk, allowing the fund to hold positions longer than institutional venture capital firms.

The fund has no direct operational or ownership connection to the Walt Disney Company, a publicly traded corporation. Shamrock Holdings manages the personal wealth of Roy E. Disney's family; Roy E. Disney was the nephew of Walt Disney and a longtime senior executive and shareholder of the Walt Disney Company until his death in 2009.

All final investment decisions trace to Stanley Gold, president and CEO of Shamrock Holdings, who has led the Disney family's investment operations for four decades. The specific investment team based in Tel Aviv has not been publicly identified in detail.

The fund is known to co-invest alongside institutional venture capital and growth-equity firms, though it typically seeks lead-investor or co-lead positions to secure board representation and governance rights. Its permanent-capital structure can make it an attractive syndication partner for GPs seeking long-duration co-investors.